The 5-year OS for the robotic, VATS, and open matched groups were 77.6%, 73.5%, and 77.9%, respectively, without a statistically significant difference; corresponding 5-year DFS were 72.7%, 65.5%, and 69.0%, respectively, with a statistically significant difference between the robotic and VATS groups (P ¼ 0.047). However, multivariate analysis found that surgical approach was not independently associated with shorter OS and DFS. Conclusions: Minimally invasive approaches to lobectomy for clinical stage I NSCLC result in similar long-term survival as thoracotomy. Use of VATS and robotics is associated with shorter length of stay, and the robotic approach resulted in greater lymph node assessment.
D
espite the increasing use of minimally invasive procedures in recent years, thoracotomy remains the most common approach for lobectomy in the United States. [1] [2] [3] However, multiple studies have demonstrated clear benefits of video-assisted thoracic surgery (VATS) over the traditional thoracotomy approach for early-stage nonsmall cell lung cancer (NSCLC), including decreased length of hospital stay, decreased short-term postoperative pain, fewer complications, [1] [2] [3] [4] [5] and even superior survival for unclear reasons. 6 In recent years, robotic lobectomy has been increasingly used for early-stage NSCLC, owing to its advanced features, including 3-dimensional visualization and small-wristed instruments, which can facilitate complex movements in a closed space. Technique feasibility, [7] [8] [9] [10] [11] [12] [13] complications, [14] [15] [16] [17] [18] [19] [20] and costs [20] [21] [22] [23] [24] have been reported for robotic lobectomy. However, robust long-term data are lacking for robotic lobectomy used to treat NSCLC, [25] [26] [27] and survival comparisons between robotic, VATS, and open lobectomy have not yet been reported.
In this study, we compare the outcomes among robotic, VATS, and open lobectomy in patients with clinical stage I NSCLC, with the purpose of evaluating the long-term overall survival (OS), diseasefree survival (DFS), and perioperative outcomes of robotic lobectomy compared with propensity score-matched groups of patients treated with VATS or open lobectomy.
METHODS

Patient Selection
This study was approved by the Institutional Review Board at Memorial Sloan Kettering Cancer Center (MSKCC). The study was conducted using data from a prospective database, comprising 2389 consecutive patients surgically treated for clinical stage I lung cancer at MSKCC between January 2002 and December 2012.
All patients included in the analysis fit the following criteria: the disease was histologically defined NSCLC; the disease was clinical stage I by the seventh American Joint Committee on Cancer (AJCC) staging system 28 ; the patient underwent lobectomy; and the resection was not preceded by preoperative induction therapy.
We excluded patients with a history of concurrent malignant disease or other previous primary cancers, patients with small cell From the
Surgical Procedures
This study covered a period of technology and technique transition at MSKCC. The choice of surgical approach of lobectomy was at the discretion of each individual surgeon. The details of the robotic, 14, 26 VATS, and open lobectomy procedures have been described previously. 6 Overall, minimally invasive lobectomy (VATS or robotic) techniques conformed to the Cancer and Leukemia Group B (CALGB) 39802 consensus technique on VATS lobectomy. 29 VATS lobectomy was performed via a 4-cm utility incision in the mid-axillary line, at the fourth or fifth intercostal space, without rib spreading. A port at the eighth intercostal space, at the anterior axillary line, was used for camera visualization, and a posterior port was used for lung retraction and stapler insertion. In the case of robotic lobectomy, a 3-arm or 4-arm approach utilizing similar incisions to the VATS approach and the da Vinci Robotic System (Intuitive Surgical, Mountain View, CA) was used. Thoracotomy lobectomy was performed through a posterolateral incision with either partial (serratus anterior) or full muscle sparing (both serratus anterior and latissimus dorsi). Systematic hilar and mediastinal lymph nodal dissection or sampling was performed in every case. Conversion was defined as the use of a rib-spreading thoracotomy at any point after initiation of a robotic or VATS dissection.
Follow-up
Data regarding disease status and survival were recorded in the database from information provided at subsequent surveillance and treatment visits at our institution. For patients receiving additional treatment and/or follow-up outside of our center, information regarding their status was obtained by telephone follow-up or outside correspondence received by caregivers. Date and mode of death were obtained from various sources, including in-house deaths, Social Security Death Index updates, Medicare database searches, and death notifications from caregivers via physician offices to the Cancer Registry's Death Notification mailbox.
Statistical Analysis
Patients were characterized by demographic and clinical variables, including age, sex, smoking history (current, former, or never), clinical stage (IA or IB), grade (well, moderately, poorly/ undifferentiated, or unknown), forced expiratory volume in 1 second (FEV1), and spirometry diffusion capacity (DLCO). Differences in patient characteristics among the 3 surgery groups were evaluated using chi-square tests for categorical variables and 1-way analysis of variance (ANOVA) tests for continuous variables.
Overall survival was defined as the time from surgery until death from any cause, with patients who did not die during the study period censored at the date of the last available follow-up. DFS was defined as the time from surgery until recurrence or death from any cause. OS and DFS were estimated using the Kaplan-Meier method and were compared across groups using univariate and multivariate Cox proportional-hazards models in the full cohort.
Differences in patient characteristics among the surgical groups suggested that treatment assignment was subject to selection bias, which may not be completely accounted for in multivariate modeling. Therefore, we used a multinomial logistic model to construct propensity scores, an index for each patient representing the probability of receiving each type of surgical treatment. Each patient who underwent the robotic approach was matched with replacement with 1 VATS and 1 thoracotomy patient with similar propensity scores (within 3% probability of having a robotic procedure), resulting in surgical groups with similar probabilities of being assigned each type of surgery. The variables used for propensity score matching were age, sex, smoking history, clinical stage, tumor cell differentiation grade, FEV1, diffusion, and pathology. Propensity score matching creates treatment groups in a way that approximates the effect of randomization, and therefore partially removes the bias that typically accompanies treatment assignment in nonrandomized studies. It should be noted that because of matching with replacement, some patients who underwent VATS and thoracotomy were matched to more than 1 patient who underwent the robotic approach.
Univariate analyses for DFS and OS were repeated in the matched cohort using Cox models clustered by matched group (ie, triplet of matched patients, 1 from each surgical group). The surgery effect for OS and DFS was then evaluated in the matched surgical groups using a multivariate Cox regression model adjusted for patient characteristics and clustered by matched group.
All statistical tests were 2-tailed, and P < 0.05 was considered statistically significant. Statistical analyses were performed using SAS 9.2 (SAS Institute) and R, using the ''survival,'' ''survcomp,'' and ''nnet'' packages (version 3.1; R Development Core Team).
RESULTS
Patient Characteristics in the Unmatched Cohort
In total, 2132 cases fit the criteria for inclusion in this study: 184 robotic, 761 VATS, and 1187 open lobectomy. Almost two-thirds of patients treated with VATS were women (P ¼ 0.006); 80% of patients treated with robotic surgery or VATS were clinical stage IA, compared with only 60% of thoracotomy patients (P < 0.001). The average pulmonary function (FEV1 percentage and DLCO percentage) was also slightly better in the robotic and VATS groups than in the open group (both P < 0.001). Age, smoking history, tumor location, and tumor cell differentiation grade were similar among the 3 groups (Table 1) .
Survival Comparison in the Unmatched Cohort
A multivariate analysis of OS in the full cohort revealed associations with age, sex, tumor differentiation, and pulmonary function ( Table 2 ). There was a trend of worse survival for thoracotomy patients, compared with robotic patients [hazard ratio (HR) 1.41, P ¼ 0.063], but there was no evidence of a significant difference between VATS patients and robotic patients.
Patient Characteristics of the Propensity Scorematched Patients
After propensity score matching, 172 cases were included in each surgical group (516 cases total). Because control subjects in the VATS and open groups were selected with replacement, the total number corresponds to 470 unique patients (172 of the 184 robotic patients, 141 of the 761 VATS patients, and 157 of the 1187 open patients were selected). Patient and disease characteristics were wellbalanced among the 3 matched groups (Table 3) . Table 4 summarizes surgery-related outcomes. Two patients died within 90 days of surgery, including 1 operative death (VATS group) because of pneumonia at day 50 after surgery. The other patient (open thoracotomy group) died of distant metastasis at day 89 after surgery. The rates of surgical complications were comparable among the 3 cohorts of patients (P ¼ 0.55), but the median length of hospital stay was shorter for the minimally invasive groups (P < 0.001). The conversion rate from minimally invasive approaches to thoracotomy was comparable between the robotic group and the VATS group (P ¼ 0.32). The most frequent postoperative complications were arrhythmia, prolonged air leak, pneumonitis, pneumothorax, and atelectasis among the 3 cohorts of patients. The detailed types and grades of complications are listed in Tables S1 to S3 (http:// links.lww.com/SLA/A995, online only). The median number of stations of lymph nodes sampled in the robotic group was higher than that in the VATS or thoracotomy group (P < 0.001). The migration from clinical stage I to more advanced pathologic stages after surgery was comparable among the 3 groups (P ¼ 0.13).
Surgery-related Outcomes of the Propensity Scorematched Patients
Survival Comparison in Propensity Score-matched Patients
The median follow-up time among survivors was 52.7 months for all the matched cases [open 65.1 months (range 0.3-147.8); VATS 52.7 months (range 5.5-127.5); robotic 39.8 months (range 0.6-137.9)]. Recurrence occurred in 25 cases, 33 cases, and 37 cases for the robotic, VATS, and open matched groups, respectively. The 5-year OS for the robotic, VATS, and open matched groups were 77.6%, 73.5%, and 77.9%, respectively. There was no significant difference in OS among the 3 groups (Fig. 1) . Younger age, never smoking, clinical stage IA, adenocarcinoma, better pulmonary function, and well-differentiated tumor cells were prognostic factors favoring OS in univariate analysis (Table 5) . Only younger age, well-differentiated tumor cells, and better DLCO remained independently associated with better OS in multivariate analysis (Table 6 ). Surgical approach was not associated with OS.
The robotic group had better DFS than the VATS group in univariate analysis (Fig. 2 ), but this result was not confirmed by multivariate analysis. Younger age, never smoking, clinical stage IA, adenocarcinoma, better pulmonary function, and well-differentiated tumor cells (compared with poorly differentiated or undifferentiated) were also prognostic factors favoring DFS in univariate analysis (Table 7) . Younger age, never smoking (compared with current smokers), clinical IA, well-differentiated tumor cells, and better DLCO remained independently associated with better DFS in multivariate analysis (Table 8) .
DISCUSSION
In recent years, robotic lobectomy has been shown to be a feasible minimally invasive approach, compared with VATS and thoracotomy, 30 but the long-term survival data for patients with NSCLC are lacking. In previous studies, we reported the long-term oncologic outcomes of robotic surgery for the treatment of earlystage NSCLC. [25] [26] [27] However, these studies [25] [26] [27] did not include a comparative arm of VATS or thoracotomy patients. In the current study, we compared long-term survival outcomes and postoperative outcomes among robotic, VATS, and open lobectomy approaches in patients with clinical stage I NSCLC by use of a propensity scorematched database. Our results suggest that surgical approach is not associated with OS in patients with clinical stage I NSCLC. This is in 
Annals of Surgery
contrast to previous publications suggesting a survival advantage to a VATS approach over thoracotomy that was independent of stage (5-year OS, 79% for VATS vs 75% for thoracotomy; P ¼ 0.08). 6 The robotic approach resulted in more stations of lymph nodes sampled than the VATS and open approaches, and the MIS approaches were associated with shorter chest tube duration and length of hospital stay. This is consistent with prior, large series of VATS and robotic pulmonary resection. Patients who underwent the robotic approach had better DFS than the patients who underwent VATS, although this result was not confirmed by multivariate analysis. A recent review of the State Inpatient Database demonstrated that robotic pulmonary resections have increased from 0.2% of all pulmonary resections in 2008 to 3.4% in 2010. 3 In our study, in the raw, unmatched database, the robotic approach accounted for 8.6% (184/2132) of resections, which is much higher than the number in the national database; however, the higher percentage in our population is consistent with the fact that the robotic approach is used with a higher prevalence in large-volume hospitals. 3 Whether the robotic or open approach results in less morbidity remains a matter of debate. Using the Nationwide Inpatient Sample, Paul et al 20 recently reported that robotic-assisted lobectomy was associated with a higher rate of intraoperative injury and bleeding, compared with thoracoscopic lobectomy. In the current study, there was no difference in conversion rate to thoracotomy with either the robotic or VATS approaches. Three conversions in the robotic group were for bleeding, but none of those patients required transfusion or greater extent of resection as a result.
Some studies have suggested that the robotic approach is associated with less morbidity than the open approach, 3, 18 whereas others have suggested that morbidity is comparable between the 2 studies. 17, 19 We observed that complication rates and severity were (6) 6 (4) 10 (6) Data are no. (%) of patients, unless otherwise noted.
Ã
Due to extensive adhesion (5 cases), inadequate single lung ventilation (3 cases), technique inability to advance instrument through assistant ports (2 cases), poor visualization for delayed atelectasis and body habitus (1 case), technical problems with anesthesia machine (1 case), and enlarged but benign appearing hilar lymph nodes (1 case).
yDue to extensive adhesion (1 case), inadequate single lung ventilation (2 cases), enlarged but benign appearing hilar lymph nodes (2 cases), unable to palpate lesions (2 cases), multiple lesions (1 case).
zTwo patients had stage 0 disease, both in the thoracotomy group. §One patient had stage IV disease (multiple pleural metastases) in the robotic group. LN indicates lymph node; LOS, length of stay in hospital. comparable among the 3 cohorts, whereas the length of hospital stay was shorter in the minimally invasive groups than in the open group. This is likely the result of more timely removal of chest tubes and quicker transition to oral pain medication. However, due to the retrospective nature of this study, there were no reliable data about the duration of chest tube drainage or the degree of postoperative pain in the medical record or the prospective database. The lack of these data is a limitation of the study.
Results of the American College of Surgery Oncology Group Z0030 Trial showed that there was no difference in the number of lymph nodes removed by VATS compared with open resections (median nodes removed: 15 vs 19; P ¼ 0.17). 31 Owing to the advantages of 3-dimensional optics, the stable camera platform, and the flexible instrumentation, 1 potential strength of the robotic approach is the thoroughness of the lymphadenectomy. Our results support this hypothesis, as more stations of lymph nodes were sampled in the robotic group than in the VATS or open groups. In addition, the proportion of pathological N1 category in the robotic group was higher than that in the VATS and open groups, indicating that the robotic approach might achieve more accurate nodal staging. Nevertheless, the difference of nodal categories and TNM upstaging was not statistically significant among the 3 groups. The small number of nodal-positive cases may contribute to this result. We think this would change with the inclusion of more patients. Using the Society of Thoracic Surgeons database, Wilson et al 32 recently reviewed 302 patients with clinical stage I NSCLC after robotic lung resection, with the purpose of determining the rate of nodal upstaging. Their findings demonstrated that pathologic nodal upstaging occurred in 6.6% of patients who were pN1 and 4.3% of patients who were pN2. 32 This finding was similar to ours, but, unfortunately, no comparison groups were included in their study. 32 However, contrasting results have also been found. Using the Society of Thoracic Surgeons database, with a large volume of 11,531 cases, Boffa et al 33 reported that N1 upstaging was significantly lower in the VATS group than in the thoracotomy group (6.7% vs 9.3%; P < 0.001). However, 167 participants were involved in the study by Boffa et al. 33 When only VATS-predominant participants were included in the analyses, the prevalence of upstaging from cN0 to pN1 was identical (8.7%) between the VATS group and the open group. 33 At MSKCC, we also perform a large proportion of cases using minimally invasive approaches. From this perspective, our results are similar to those of Boffa et al. 33 Licht et al 34 recently reported the outcomes of 1513 patients with clinical stage I NSCLC, using the Danish Lung Cancer Registry database; they found less upstaging in the VATS group than in the thoracotomy group, for both the N1 category (8.1% vs 13.1%; P < 0.001) and the N2 category (3.8% vs 11.5%; P < 0.001). Nevertheless, the national databases may suffer from selection bias, as the field of lymph node dissection and the individual surgeon's skills and expertise may vary dramatically among different institutions. Similar to the current study, previous studies using data from single institutions have reported that the efficacy of lymph node dissection was comparable between VATS and open lobectomy. 35, 36 The current literature lacks long-term survival comparisons among robotic, VATS, and open lobectomy for patients with earlystage NSCLC. Wilson et al 32 reported only 2-year survival for patients treated with the robotic approach, owing to a short duration of follow-up; however, OS and DFS for robotic lobectomy in their study were comparable with those for VATS and thoracotomy in the historical data. We have previously reported the long-term survival prognosis of robotic surgery for the treatment of early-stage NSCLC, but comparison groups were not included. [25] [26] [27] The current study is important because, to our knowledge, it is the first to compare longterm OS and DFS among robotic, VATS, and open lobectomy in the treatment of patients with clinical stage I NSCLC. In this study, we used propensity score matching to minimize the bias involved in treatment assignment. The use of propensity score matching and large sample sizes should increase the reliability of our results.
There were no significant differences in OS and DFS observed in our propensity-matched cohorts of robotic, VATS, and open lobectomy. On the basis of our findings, and also the historical reports, we see promise in expanding patient access to robotic lung resections. A recent analysis using the State Inpatient Database found that, although the percentage of VATS lung resections has been increasing, thoracotomy was used in 56.6% of cases in 2010. 3 The disadvantages of VATS, such as the 2-dimensional view, camera tremor, and less freedom of instrumentation, result in a deep learning curve and, thus, hinder its widespread use. 16 The limitations of this study must also be considered. First, although propensity score matching was performed to decrease selection bias among groups, bias might also exist due to the retrospective nature of the study. For example, the extent of lymph node removal might vary among cases. Nevertheless, since there are no clear standards on the surgical procedures for robotic and VATS lobectomy, and since the favored surgical approach varies dramatically among surgeons, it would likely be difficult to set up a randomized controlled clinical trial to compare the survival prognosis among robotic, VATS, and open approaches in patients with NSCLC. Second, because of the retrospective nature of this study, we did not compare costs, but the cost of robotic technology, especially in a time of increasing healthcare expenditures, may be a real issue. Nevertheless, we believe that with advances in the robotic technique, the device-related costs will decrease. Third, due to the retrospective nature, the time points for surveillance may not be necessarily consistent among groups, and this may impact the comparison of survival outcomes. In this study, some patients achieved long-term survival of over 10 years after surgery; however, the median followup time was 52.1 months for all the matched cases. We believe that a longer follow-up time is necessary to update the survival outcomes in the future. Lastly, the number of factors included in our propensity score model was limited by the data available for this cohort. An ideal model would include more factors.
In conclusion, after propensity score matching, there is no difference in OS between surgical approaches for lobectomy in the treatment of patients with clinical stage I NSCLC. Moreover, surgical 
